In 2016, the world's top ten best-selling biopharmaceutical forecasts, Humira leads the way, Roche is the top three
As 2015 is about to pass, the sales of major biopharmaceuticals will continue to grow linearly. If you look at the sales of these best-selling drugs for billions or even billions of dollars, you will understand why pharmaceutical companies are making great efforts in research and development. This also directly promotes the continued development of biopharmaceuticals.
The following comprehensive analysis predicts the top ten best-selling biopharmaceuticals in the world in 2016. From the perspective of properties, monoclonal antibodies, interferons, insulin are still the main force. Indications are mainly for the treatment of cancer, rheumatoid arthritis, diabetes and other common chronic diseases. The traditional pharmaceutical giant Roche is in the top three, but Abbott’s humrira will be far ahead, occupying the top spot.
The world's best-selling biopharmaceutical ($100 million) in 2016
Data source: listed company report
Avonex is an injectable beta-interferon for the treatment of multiple sclerosis. Its market is very mature. It has unique pharmaceutical and cryopreservation technology, so it has an advantage in competition with generic drugs. It is still Biogen's in 2014. The highest-volume drug, sales in 2014 reached $3 billion. The drug expired in December 2013, and it is bound to be impacted by generic drugs. Its sales will continue to decline in the next few years, and it is expected to fall to around $1 billion in 2018. However, there is news that Biogen is trying to increase the price of drugs in order to stabilize sales. Such an approach is bound to cause dissatisfaction among patients, which may be counterproductive.
TOP9 Novo and NovoRapid
Novo is an insulin analogue produced by Novartis. Novo has many benefits compared with conventional human insulin. Its pharmacological action can better simulate the insulin secretion pattern of normal people during meals. It is currently ideal. Postprandial hyperglycemia control drugs, which promote the administration of insulin more perfect. Its biggest competitor is the courtesy Humalog. Although the patent for this drug has expired in June 2014, its good results have been accepted by the majority of patients. Biosimilars will not affect its sales in a short period of time. It is expected that sales will remain above US$3 billion in the next few years and continue to grow.
Neulasta is the world's first long-acting rhG-CSF product launched by Amgen in 2002. It stimulates the production of white blood cells and reduces the side effects of anti-tumor chemotherapy. It increases the molecular weight of drugs by PEG (polyethylene glycol) and slows down it. The clearance rate in the body thus effectively prolongs the half-life of the drug, reducing the frequency of injection administration to multiple times per chemotherapy course, reducing the pain caused by frequent injections, and serious infections during chemotherapy. The disease is frequently interrupted by the treatment, and the patient's compliance is greatly improved. In 2002-2014, sales of Neulasta increased from US$464 million to US$4.688 billion, and sales in the 12-year period increased by 9 times, with a compound annual growth rate of 22.7%.
Roche's Herceptin is the gold standard for the treatment of HER2-positive diffuse breast cancer. Its active ingredient is trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. However, the market has become saturated and sold. The rate of increase has slowed down. In addition, Roche's Perjeta and Kadcyla have been listed to replace Herceptin in response to competition for biosimilars. A variety of research biopharmaceuticals in Herception threaten Herceptin's sales market. However, it still has annual sales of 6.275 billion in 2014. Due to competition from generic drugs, its annual sales will shrink. It will fall to $5.8 billion in the year.
TOP6 comes time
Sanofi's Lantus is a long-acting insulin analogue that is mainly used to treat type 2 diabetes. It competes with Pfizer's Levemir in this respect. Lilly also has biosimilars for this drug, which was awarded in May 2015. Batch, but in the process of US approval, Sanofi caused a patent dispute. Affected by this, Lantus' sales in the third quarter fell by 5.4%. Sanofi complained that patients gave the company a lot of price pressure, they had to lower the price to ensure sales, the effect can be seen from the sales performance in the fourth quarter of 2014, sales growth is higher than 17%, 2014 Sales reached $6.344 billion.
Avastin is a monoclonal antibody. As an anti-angiogenic drug, it blocks the tumor by inhibiting the action of vascular endothelial growth factor, inhibits the spread of tumors in the body, and enhances the efficacy of chemotherapy. In 2011, the FDA claimed that the US mammary gland and the European breasts were not the same as the market, and the sales volume dropped by 18%. It is currently picking up and still maintains its status as the main treatment for diffuse breast cancer in Europe. 11 years later, it was approved by the FDA/EU for the treatment of first-line colorectal cancer. Another good news is that the FDA will recently approve its priority treatment for uterine and ovarian cancer. In 2014, sales reached $6.417 billion, with With the increase in indications, it can be predicted that its sales will stay at its peak for several years.
TOP4 Mei Luohua
The famous rituximab is the world's first monoclonal antibody drug approved for the treatment of non-Hodgkin's lymphoma, and was subsequently approved for the treatment of multiple lymphomas and blood cancers. It is also a rheumatoid joint. Inflamed second-line drugs. The good therapeutic effect of rituximab has made many generic drug companies eager to start experimenting with generic drugs. But in fact, the competitor of rituximab comes mainly from its own: Roche began to produce its substitute: Gazyva, various clinical studies show that Gazyva has better efficacy than rituximab, and it is certain that rituximab The market space for monoclonal antibodies will be constantly seized by this younger brother.
Enbrel is a TNFα inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing joints. Its active ingredient is recombinant human tumor necrosis factor receptor p75 Fc fusion protein. Enli was jointly sold by Pfizer and Amegen. Amgen took over all of its markets in the US, and Pfizer was responsible for buying Enbrel outside the US. The company's report showed that their sales in 2014 were 4.69 billion and 3.85 billion, respectively. It should be noted that the US dry powder patent has expired and the water solvent type agent will not expire until 2023. A variety of biosimilars are under development, including a drug from Snadoz in advanced trials, while India's Cipla generics have been approved.
TOP2 class gram
Remicade is a TNF antibody for the treatment of Crohn's disease, rheumatoid arthritis, and psoriatic arthritis. The company once worried that Pfizer's new oral drug Xeljanz would pose a threat, but it turns out that the fear is superfluous. Its main threat comes from generic drugs: the European Agency for Drug Control has approved the biosimilars of Celltrion and Hospira's Remicade, called Remsima, fortunately these drugs are only marketed in a small number of markets in Europe where Johnson & Johnson has lost patent protection. The effects of the impact of pharmaceuticals will only fully show up in the coming year. In general, Remicade has not been affected by biosimilars, but sales have continued to rise, not even affected by supply chain changes.
TOP1 Xiu Mei Le
The 2014 biopharmaceutical sales champion was Amber's Humira, which had sales of $12.5 billion, nearly double the second infliximab. Humira, also known as adalimumab, can slow down rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Recently, it has applied for a variety of indications such as axial-type spondyloarthritis. Injecting in the patient's home is much more convenient than other drugs that relieve the condition. Interestingly, some recent so-called human-antibody competitors such as Johnson's Simponi and UCBA's Cimzia did not reduce Humira's sales, let alone Pfizer's oral Xeljanz. Its tens of billions of dollars in annual sales is really eye-opening, patents will expire in 2016, it is conceivable that the world's major generic companies have been eyeing, and even began to develop its generic drugs. Aber applied for a franchise to the FDA for this purpose. In the third quarter of 2014, sales increased by 17%, and the growth momentum continued unabated. The main problem now is that the franchise can maintain this growth momentum. The good news is that patients do not seem to be in conflict with the price issue, and the price has There is room for growth, and it seems that no drug will threaten its leading position in the next few years.
(Jilin Qijian Biotechnology Co., Ltd._www.qjbio.com.cn)